The batch issuance of the quadrivalent HPV vaccine has dramatically decreased, and chongqing zhifei biological products' revenue and net profit have both declined. Interpretation of the financial report.
① Chongqing Zhifei Biological Products reported a decrease in revenue and net income for the first half of the year due to a decline in sales of its main product. ② The batch issuance of Merck's quadrivalent HPV vaccine, which the company represents, decreased by over 90% year-on-year. ③ As the development of domestically-produced nine-valent HPV vaccine accelerates, the company's pressure will further increase.
The decline in the pharmaceutical sector is affecting overall revenue. Fosun Pharma: Will focus on building super 1 billion yuan big varieties | Earnings conference highlights.
Fosun Pharma's revenue from innovative drugs in the first half of the year exceeded 3.7 billion yuan, accounting for about 18% of the overall revenue. Wu Yifang revealed that the business of innovative drugs will strive to achieve a compound annual growth rate of 30% in the next few years. Wu Yifang said that the privatization of Henlius is currently underway, and the entire business and pipeline of Henlius will be deeply integrated with Fosun Pharma through privatization.
Intense market competition combined with inventory reduction, Shenzhen Kangtai Biological Products' performance in the first half of the year has significantly declined | Interpretation of financial reports
①Affected by market competition and factors such as inventory reduction, the total revenue and net income attributable to the mother of shenzhen kangtai biological products declined in H1. ②The sales revenue of the business sector with the largest revenue contribution of the company decreased by more than 30% year-on-year. ③The accounts receivable of shenzhen kangtai biological products continued to climb, with a substantial decrease in cash flow.
Shenzhen Salubris Pharmaceuticals' H1 revenue increased by 20%, but net profit growth declined. The launch of two new drugs is facing negotiations with the government.|Interpretations of the financial report
1. In the first half of this year, the revenue of Shenzhen Salubris Pharmaceuticals increased by over 20%, but the net profit attributable to the parent only realized a growth of less than 2%; 2. During the reporting period, Shenzhen Salubris Pharmaceuticals had two innovative products approved for listing, and both products have now passed the national preliminary review this year; 3. Shenzhen Salubris Pharmaceuticals has 4 new drugs currently under market approval, including three chemical drugs and one biological drug.
beijing wantai biological pharmacy enterprise's application for the listing of the nine-valent HPV vaccine has been accepted, but the stock price is "handsome for only three seconds"?
① Beijing Wantai Biological Pharmacy Enterprise has received the acceptance notice from the Drug Evaluation Center of the National Medical Products Administration for the application of the marketing authorization of its nine-valent HPV vaccine. ② The stock price of Beijing Wantai Biological Pharmacy Enterprise rose sharply this afternoon, but quickly fell back. As of the close of today, the increase was 3.9%. ③ In addition, Beijing Wantai Biological Pharmacy Enterprise is still facing fierce competition from its rivals in the field of nine-valent HPV vaccines.
Express News | Biomedical stocks in Hong Kong continued to rise in the afternoon, with Wuxi Bio up nearly 7%, Wuxi Apptec and Wuxi Huijian up more than 5%, Innocare and Beigene up more than 4%.